Document hub

Our international presence

Return to Hikma.com
Contact Us

Popular searches

Sitemap

Home
Who we are
Purpose, strategy and culture
Impact
Leadership
Victoria Hull Said Darwazah Mazen Darwazah Khalid Nabilsi Douglas Hurt Ali Al-Husry Cynthia Flowers Laura Balan Dr Deneen Vojta Helen Middlemist Hussein Arkhagha Bassam Kanaan Susan Ringdal Hafrun Fridriksdottir Julie Hill Sam Park
History
Corporate governance
Codes and ethical standards
Policy positions and statements
What we do
Our businesses
Operations
R&D
Products
Contract manufacturing
Injectables contract manufacturing Hikma Rx contract manufacturing
Partnering with Hikma
Hikma Ventures
Responsibility
Advancing health and wellbeing
Access to medicines Product quality and safety Social responsibility
Empowering our people
Protecting the environment
Upholding ethical standards and acting with integrity
Partnerships and stakeholders
Awards and recognition
Suppliers
Sustainability reports
Responsibility
Investors
Recent results
Why invest
Strategy
Results and presentations
Regulatory news
Email alert sign-up
Company compiled consensus
Analyst coverage
Financial calendar
Investor tools
Share price lookup Share graph Share series Investment calculator
Shareholder information
Manage your shareholding Shareholder meetings Dividend information Share listings and depositary receipts
2025 Annual Report
Corporate factsheets
Careers
Search jobs
Roles at Hikma
Why Hikma
News
Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic® into the Saudi, Jordanian and Iraqi Markets
Hikma and Guardant Health sign exclusive partnership agreement to bring transformative cancer diagnostic technology to the Middle East and North Africa
Hikma launches authorized generic of Xyrem® (sodium oxybate) in the US
Hikma and Celltrion Healthcare sign new exclusive licensing agreement for Vegzelma® for the Middle East and North Africa region
Hikma expands addiction therapy portfolio with the launch of Naloxone Hydrochloride Injection, USP, in prefilled syringe
Hikma to present at 41st Annual J.P. Morgan Healthcare Conference
Notice of preliminary results
Hikma delivers a resilient underlying performance in 2022
Hikma expands impact in Canada with launches of new sterile injectable medicines
Hikma launches Cefazolin for Injection, USP, in the US
Hikma launches Icosapent Ethyl Capsules, 0.5g, in the US
Hikma launches Labetalol Hydrochloride Injection, USP in prefilled syringe
Hikma launches Posaconazole Oral Suspension in the US
Riad Mishlawi named Chief Executive Officer of Hikma Pharmaceuticals PLC
Hikma launches Regadenoson Injection in prefilled syringe
Good momentum across all businesses and updated Generics guidance
Hikma launches Diazepam Injection, USP in the US
Hikma exceeds 150 injectable medicines in the US with launch of Dobutamine Injection, USP
Hikma launches Neostigmine Methylsulfate Injection, USP in prefilled syringe
Hikma launches Midazolam in 0.9% Sodium Chloride Injection in the US
Notice of results
Hikma appoints new President of Injectables business
Hikma and Rakuten Medical sign exclusive licensing agreement for AlluminoxTM platform cancer treatment for the Middle East and North Africa
Hikma Launches New 503B Sterile Compounding Business
Hikma to present at 40th Annual J.P. Morgan Healthcare Conference
Hikma expands into Canada with acquisition of Teligent sterile injectable assets
Hikma Ventures leads Series A extension in NuvoAir to support its platform for patient-centric care and clinical trials
Hikma signs license agreement with Medicine Patent Pool for molnupiravir
Hikma launches Diazepam Injection, USP in single-dose prefilled syringe
Hikma completes acquisition of Teligent sterile injectable assets
Hikma expands licensing agreement with Celltrion for Remsima® subcutaneous formulation in MENA
Notice of preliminary results
Hikma delivers another year of profitable growth in 2021 and announces share buyback
Hikma Ventures leads Series B extension in Activ Surgical to support the global commercialization of its platform
Hikma launches Benztropine Mesylate Injection, USP
Hikma Ventures Participates in USD 44 Million Financing Round for Altibbi to Expand the Platform’s Reach across MENA
Hikma Ventures invests in Tact.ai, an AI-powered customer engagement platform for life sciences companies
Hikma Ventures leads seed financing round for Egypt based O7 Therapy; a mental health service provider for Arabic-speakers worldwide
Hikma confirms FTC preliminary approval for Custopharm
Hikma completes acquisition of Custopharm
Continued strategic progress and updated full year guidance following Custopharm acquisition
Hikma updates Generics guidance for 2022
Siggi Olafsson to step down as Chief Executive
Section 430(2B) Companies Act 2006 Statement
Hikma enters the French generic injectables market, expanding European presence
Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region
Notice of results
Hikma’s diversified business delivers resilient H1 performance
Hikma launches RYALTRIS™ seasonal allergic rhinitis nasal spray in the US
Hikma launches Bortezomib for Injection
Hikma launches Fulvestrant Injection
Hikma appoints Victoria Hull and Laura Balan as Directors
Hikma appoints Deneen Vojta, M.D. as a Director
Hikma launches first prefilled syringe of Succinylcholine Chloride Injection, USP
Hikma reiterates full year segmental guidance, with strong momentum in Injectables and Branded
Hikma and Celltrion Healthcare sign exclusive licensing agreement for ustekinumab for the Middle East and North Africa region
Hikma Injectables Portugal site visit
Hikma launches Levothyroxine Sodium Injection in ready-to-use vials
Hikma and Junshi Biosciences sign exclusive licensing agreement for cancer treatment drug toripalimab for the Middle East and North Africa region
Hikma’s commitment to environmental performance recognised with “A-” rating in 2020 CDP Global Climate Change Report
Hikma provides update on generic Advair Diskus® launch
Potential Acquisition
Hikma Participates in the Virtual 51st World Economic Forum Annual Meeting
Hikma launches Ephedrine Sulfate Injection, USP
Notice of preliminary results
Hikma launches Thiamine Hydrochloride Injection, USP
Hikma donates over $4 million USD in medicines and signs new long-term partnerships with Dispensary of Hope, Direct Relief, Americares, Brother’s Brother Foundation, and the National Children’s Cancer Society
Hikma delivers strong performance in 2020
REMINDER Analyst and investor live Q&A call
Meet the Management Series
Hikma launches generic version of Northera®
Hikma and GSK agree to cease potential acquisition discussions in Egypt and Tunisia
REMINDER Injectables Meet the Management 24 March 2021, 2:00pm to 3:30pm
Hikma pledges additional $40,000 to local US food banks and pantries in fight against hunger
Hikma resumes launch of generic Advair Diskus®
Hikma announces exclusive agreement with AFT Pharmaceuticals for injectable non-opioid pain medication Combogesic® IV in the US
Hikma and Melinta Therapeutics sign exclusive licensing agreement for two novel anti-infectives for the Middle East and North Africa region
Hikma announces good start to 2021 and reiterates full year guidance
Hikma announces US FDA approval of KLOXXADO TM (naloxone hydrochloride) nasal spray 8mg
Hikma launches Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection
Hikma launches Docetaxel Injection, USP
Hikma launches Hydralazine Hydrochloride Injection, USP
Meet the Management Series – Branded
Hikma launches Labetalol Hydrochloride Injection in ready-to-use bags
Hikma launches Estradiol Valerate Injection, USP
Hikma appoints Patrick Genestin to lead Generics Business Development
REMINDER Branded Meet the Management 22 June 2021, 2:00pm to 3:00pm
Hikma launches Ganciclovir for Injection, USP
Hikma launches Rufinamide Tablets
Hikma launches Doxycycline for Injection
Hikma launches Succinylcholine Chloride Injection, USP
Notice of results
Hikma announces US launch of KLOXXADOTM (naloxone HCl) nasal spray 8mg
Hikma delivers another strong financial and operational performance and improves FY outlook for Generics
Meet the Management Series – Generics
Bio-Thera Solutions and Hikma Pharmaceuticals announce exclusive commercialization and license agreement for BAT2206 in the US, a proposed biosimilar referencing Stelara® (ustekinumab)
Hikma and FAES Farma enter into exclusive licensing agreement for the commercialisation of Bilastine tablets in the US
REMINDER Generics Meet the Management 23 September 2021, 2:00pm to 3:15pm
Hikma strengthens US Injectables business through acquisition of Custopharm
Hikma launches Micafungin for Injection
Hikma donates 50,000 doses of injectable naloxone to help expand non-profit access to lifesaving treatment for reversing opioid overdoses
Hikma and Almirall enter an exclusive licensing agreement to market Finjuve in the Middle East and North Africa region
Hikma continues strong 2021 performance and reiterates full year guidance
Hikma Ventures invests in biotechnology company BioSapien Inc., developer of a patented drug-delivery device intended to reduce the system-wide side effects of chemotherapy treatments
Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia® and Xgeva®
Hikma launches Bupivacaine HCl Injection, USP
Hikma further improves its environmental performance in 2019 CDP Global Climate Change Report
Notice of preliminary results
Hikma and Glenmark Pharmaceuticals Enter into Exclusive Licensing Agreement for Commercialising Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in the US
Hikma delivers strong growth in revenue and profit in 2019
Hikma Pharmaceuticals USA Inc. Extends Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP 30mg/mL, 1mL Fill/2mL Vials Due to the Potential Presence of Small Particulates
Hikma expands generics portfolio with Everolimus Tablets launch
Hikma supports teachers in Jordan through new partnership with Save the Children
Hikma update regarding COVID-19
Hikma launches Vecuronium Bromide for Injection
Hikma announces strong start to 2020 and reiterates full year guidance
Hikma appoints Douglas Hurt as Director
Hikma Ventures invests in Altoida, Inc., a predictive digital biomarker company using AI and AR to help predict brain diseases with up to 94% accuracy
Hikma launches Nicardipine Hydrochloride premixed injection in ready to use bags
Hikma launches Buprenorphine Hydrochloride Injection
Hikma launches employee matching donation campaign to support local US food banks and pantries
Hikma responds to COVID-19 shortage with launch of Propofol Injectable Emulsion, USP
Hikma launches Dicyclomine Hydrochloride Oral Solution
Hikma launches a generic version of Afinitor® Tablets, 2.5mg, 5mg, 7.5mg
Hikma and Sun Pharma enter into exclusive licensing agreement for ILUMYA™ for the Middle East and North Africa region
Hikma announces buy back of up to approximately £295 million of shares from Boehringer Ingelheim
Transaction in Own Shares and Total Voting Rights and Capital
Hikma successfully completes $500 million 5-year Eurobond issue
Notice of results
Hikma launches Dacarbazine for Injection, USP
Hikma improves performance in FTSE4Good Index
Hikma delivers strong first half performance and raises full year guidance
Hikma improves its performance in FTSE4Good Index
Hikma Ventures Participates in CAD4.0 million Series A Financing Round for SeamlessMD to Expand Digital Patient Engagement Leadership
Hikma launches Azacitidine for Injection
Hikma provides update on status of ANDA for generic Advair Diskus®
Hikma and Arecor expand collaboration with new agreement to develop and commercialise ready-to-administer medicine
Hikma assigned investment grade status from Fitch Ratings
Hikma launches Rufinamide Oral Suspension, 40 mg/mL
Hikma continues strong 2020 performance and updates full year guidance
Hikma launches Icosapent Ethyl Capsules
Hikma Pharmaceuticals and Sesen Bio announce exclusive partnership to commercialise Vicineum™ in MENA
Hikma launches Ropivacaine HCl Injection, USP for anaesthesia and acute pain management
Hikma launches generic Advair Diskus® following FDA approval
Hikma announces exclusive agreement with Sciecure Pharma for niche injectable anti-viral medicine
Hikma to present at 37th Annual J.P. Morgan Healthcare Conference
Hikma Participates in 2019 World Economic Forum Annual Meeting in Davos, Switzerland
Hikma launches Mitomycin for Injection, USP
Hikma launches Abiraterone Acetate Tablets
Notice of results
Hikma establishes partnership with Melinta in MENA
Hikma Board appoints Cynthia Schwalm as Director
Hikma delivers strong 2018 results and makes good strategic progress to position for future growth
Hikma launches Norepinephrine Bitartrate Injection, USP
Hikma participates in ‘World Economic Forum on the Middle East and North Africa’ at Dead Sea, Jordan
Hikma launches 100th injectable medicine in US with introduction of Vancomycin Hydrochloride for Injection, USP
Hikma sponsors MIT Grand Hack to support global healthcare innovation
Hikma announces positive start to 2019 and reiterates guidance
Hikma Ventures participates in $11 million funding round for Pillo Health
Hikma launches Bosentan Tablets
Notice of interim results
Hikma and Civica Rx sign long-term agreement to reduce generic drug shortages in the US
Hikma and Richter sign a license and supply agreement for cariprazine in MENA
Hikma launches Cisplatin Injection
Hikma remains constituent of the FTSE4Good Index Series for 5th consecutive year
Hikma appoints Dr Shahin Fesharaki as Chief Scientific Officer and Global Head of R&D
Hikma delivers strong first half results and raises full year guidance
Hikma acquisition expands nasal spray capabilities and pipeline
Hikma launches Phenylephrine Hydrochloride Injection, USP
Hikma launches Tetrabenazine Tablets
Hikma launches prefilled syringes in the US
Hikma continues strong 2019 performance and reiterates full year guidance
Hikma Ventures leads Series A financing for development of Winterlight Labs’ AI vocal technology to detect central nervous system disorders and track efficacy of treatments
Hikma completes its FDA response for generic Advair®
Hikma receives recognition for supporting United Nations Sustainable Development Goals for the second consecutive year
Civica Rx and Hikma announce shipments of Heparin and seven other essential injectable medicines
Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology
Hikma licenses Chiesi Group’s respiratory and neonatal products for Egyptian market
Hikma Joins 50th World Economic Forum Annual Meeting in Davos, Switzerland
Hikma launches Ifosfamide Injection
Hikma Pharmaceuticals Participates in World Economic Forum in Switzerland
West-Ward Pharmaceuticals Strengthens US Leadership and appoints Daniel Motto as Executive Vice President of US Injectables
Hikma Pharmaceuticals Participates in World Economic Forum in Switzerland : Marking a decade of its involvement
Sigurdur Olafsson appointed Chief Executive Officer
Notice of Results
Hikma becomes Harvard Business School Case Study as part of Corporate Governance and Making Boards Effective Modules
Hikma provides an update on the status of its ANDA for generic Advair Diskus®
Hikma starts rollout of new global brand
Hikma reports 2017 full year results
Hikma Pharmaceuticals becomes Patron of The Prince’s Trust - Supporting young people into education and employment
Hikma has launched Ritonavir Tablets USP
Hikma launches Palonosetron Hydrochloride Injection
Hikma launches Epirubicin Hydrocholoride Injection, USP
Hikma launches Dexrazoxane for Injection
Princess Ghida Talal Opens Hikma's Annual Forum for the Treatment of Leukemia and Other Blood Cancers
Hikma expands licensing agreement with Rovi for their enoxaparin biosimilar
Hikma launches Methotrexate Injection, USP and Methotrexate for Injection, USP
Hikma Organizes 10th Annual Global Volunteering Campaign
Hikma Launches Basilea’s Antibiotic ‘Ceftobiprole’ in Saudi Arabia
AGM trading update
Hikma launches Methylergonovine Maleate Tablets, USP
Hikma appoints Henriette Nielsen as Chief Transformation Officer
Hikma Announces the Close of the Roxane Laboratories Acquisition
West-Ward Pharmaceuticals now Hikma in the US as part of global rebranding
Hikma enters into licensing partnership with Perrigo in MENA
Hikma launches Bleomycin for Injection, USP
Hikma launches Daunorubicin HCl Injection
SAVE THE DATE Investor Day 8 November 2018 13.30
Hikma Acts to Ease Critical Shortage of Pain Medications Needed by US Hospitals and Their Patients
Notice of results - August
Hikma launches Sterile Water for Injection, USP
Hikma reports strong 2018 interim results and raises full year guidance
Hikma Pharmaceuticals appoints Kristy Ronco Executive Vice President, Sales and Marketing, Generics
Hikma Remains Constituent of FTSE4Good Index Series
Hikma launches AdriamycinTM (DOXOrubicin HCl) for Injection, USP
Hikma Appoints Global Head of Intellectual Property and US General Counsel
Hikma Ventures participates in a $19 million round for Click Therapeutics
Hikma Receives Recognition for Supporting United Nations Sustainable Development Goals
Hikma launches Imatinib Mesylate Tablets
REMINDER Investor Day 8 November 2018, 12.30pm for 1.30pm
Hikma updates on current trading and raises 2018 guidance
Hikma announces global agreement with Vectura to develop generic versions of GSK’s Ellipta® portfolio
Hikma launches Triazolam Tablets
Hikma announces exclusive licensing and supply agreement with Hansoh Pharma for suite of injectable oncology medicines
Hikma demonstrates support for US pharmacists and patient safety
Hikma launches Clobazam Oral Suspension and Clobazam Tablets
Hikma launches Dalfampridine Extended-release Tablets
Hikma Ventures participates in a $20.5 million Series C round for Prognos
Hikma Ventures invests in Biolinq, the next generation minimally-invasive biosensor technology company
Trading Update
Hikma wins Company of the Year at the Global Generics & Biosimilars Awards 2017
Hikma Pharmaceuticals Remains Constituent of FTSE4Good Sustainability Index
Hikma delivers stable profitability and strong cash generation in H1 and maintains a solid balance sheet
Notice of results
Hikma Pharmaceuticals Announces Leadership and Organisational Changes to US Business
Hikma Ventures Co-leads $11 million Series A round in Lemonaid Health
AGM Trading Update
Hikma Collaborates with the Department of Leukemia at the MD Anderson Cancer Center
Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency
Hikma Pharmaceuticals PLC (Hikma) will announce its preliminary financial results for the year ended 31 December 2016 on Wednesday 15 March 2017.
Hikma Pharmaceuticals Participates in 2017 World Economic Forum in Jordan
Hikma Pharmaceuticals to Publish Report on its Alignment with UN Sustainable Development Goals
Hikma Pharmaceuticals Health Partner of the World Economic Forum in Davos
Hikma update on ANDA for generic Advair Diskus
Hikma receives FDA approval for Neostigmine Methylsulfate Injection
Hikma announces revised terms for previously announced acquisition of Roxane Laboratories
Notice of Results (March 2016)
Hikma Pharmaceuticals Preliminary Results
Hikma’s ANDA for Generic Advair Diskus® accepted for filing by FDA
Hikma announces FDA approval and launch of Fluticasone 50 MCG Spray, the store brand equivalent of Flonase
Hikma acquires six injectable products in Europe
Notice of Results (August 2016)
Hikma Ventures invests in Chrono Therapeutics for the development of next generation trans-dermal drug delivery technology
Board Appointment and Succession
AGM Trading Update
HIKMA wins Mitigare / Colchicine patent infringement case
Michael Raya, CEO of West-Ward Pharmaceuticals, Hikma's wholly-owned subsidiary in the US, joins GPhA
Hikma delivers solid first half performance and reiterates full year revenue guidance of $2.0 billion to $2.1 billion
Meet the Management Day
Said Darwazah, Chairman and CEO of Hikma, awarded Global Generics “Leader of the Year”
Hikma Ventures invests in Propeller Health for the enhancement of leading respiratory technology platform
Trading Update (November 2016)
Hikma Pharmaceuticals Launches October Breast Cancer Awareness Campaign
Hikma Pharmaceuticals to participate in the world economic forum's industry strategy meeting
Hikma Pharmaceuticals Celebrates ninth annual global volunteering day
Hikma launches cancer awareness campaign
Hikma partners with the world economic forum
Hikma recieved FDA approval for Cyanocobalamin Injection
Hikma receives FDA approval for Azathioprine Sodium Injection
Hikma receives FDA approval for Rifampin Injection
Hikma receives FDA approval for Methylprednisolone Sodium Succinate Injection
Hikma receives FDA approval for Etomidate Injection
Hikma receives FDA approval for Acyclovir Injection
Hikma receives FDA approval for Temozolomide Capsules
Hikma’s ANDA for Generic Advair Diskus® accepted for filing by FDA (1)
Hikma receives FDA approval for Leucovorin Calcium Injection
Hikma receives FDA approval for Fluphenazine Decanoate Injection
Hikma receives Drug Shortage Assistance Award from US FDA
Hikma receives FDA approval for Ketamine Hydrochloride Injection
Hikma announces launch of Generic Xeloda® Tablets 150 mg and 500 mg in the US
Regulatory approval of Hikma’s colchicine is upheld
Trading update
Trading Update (November 2015)
Hikma awarded Best Company in an Emerging Market
Hikma launches phentolamine mesylate injection in the US
Hikma founder and honorary life president Samih Darwazah passes away
Hikma signs exclusive licensing, distribution and supply agreement with Basilea Pharmaceutica International Ltd. for Zevtera®
Hikma awarded Global Generics Acquisition of the Year
Hikma agrees to acquire EIMC United Pharmaceuticals, strengthening its position in the large and fast growing Egyptian market
Hikma enters into partnership with Vitabiotics for the promotion and distribution of Vitabiotics’ leading healthcare products in MENA
Hikma Pharmaceuticals Interim Results
Notice of Interim Results Announcement – Analyst Presentation
Hikma acquires Roxane Laboratories, transforming its position in the US generics market
Hikma appoints Kofi Amegashie to head its sub-Saharan Africa unit
Hikma AGM Trading Update
Notice of Prelim Results Announcement – Analyst Presentation
Hikma signs exclusive license agreement with Azanta for Nimoral
Hikma Pharmaceuticals First Jordanian Site to Receive ISO 50001 Certification
Hikma to launch colchicine 0.6mg capsules
Hikma renews UN Global Compact membership
Hikma receives high score in CDP Global Climate Change Report 2015
Hikma Pharmaceuticals goes pink for Breast Cancer Awareness Month
Hikma renews Partnership with INJAZ for Youth Programs
Hikma Pharmaceuticals supports the free Open Days at the Children’s Museum Jordan
Hikma Pharmaceuticals Launches Ramadan Community Campaign
Hikma Pharmaceuticals holds its annual Global Volunteering Day
Hikma partners against corruption and supports MENA growth markets at WEF
Hikma files for generic ZYTIGA® approval
Hikma receives approval for thiotepa injection in the US
Hikma launches caffeine citrate injection, commercialising the first of the Bedford products
Board Appointment – Dr Pamela Kirby
Interim Management Statement
Hikma Meet the Management Day London
Hikma awarded Global Generics Company of the Year for EMEA
Hikma receives approval for colchicine 0.6mg capsules
Hikma Meet the Management Day
Hikma completes acquisition of Ben Venue manufacturing site
Hikma Pharmaceuticals Interim Results
Notice of Interim Results Announcement – Analyst Presentation
Hikma agrees to acquire Ben Venue manufacturing site adding R&D capabilities and capacity
Hikma completes the acquisition of assets of Bedford Laboratories
Hikma Pharmaceuticals PLC – Acquisition of Bedford Laboratories
Interim Management Statement - May 2014
Hikma announces successful resolution to US FDA warning letter at Eatontown facility
Notice of Prelim Results Announcement – Analyst Presentation
Trading Update
Board Changes
Hikma Globalizes its Pharmacovigilance Activities
Hikma Pharmaceuticals Launches ‘You Are Hikma’ 2014 Campaign
Hikma Holds its 7th Volunteering Day
Hikma Pharmaceuticals supports and takes part in 'Earth Hour 2014'
Hikma enters partnership with Eisai for distribution of first-in-class epilepsy treatment Fycompa® in Middle East
Hikma and AUB collaborate on developing anticancer treatment from medicinal plants
Hikma signs license and supply agreement with SK Chemicals for its Rivastigmine transdermal patch
Samih Darwazah Tops Scrip Emerging Markets Leaders
Hikma signs long term supply agreement with Unilife to enhance delivery of generic injectables
Interim Management Statement
Hikma signs additional license and supply agreement with GP Pharm for its leading oncology compound for Germany and Portugal
Hikma entering Ethiopian pharmaceutical market through a joint venture with MIDROC Group
Hikma Pharmaceuticals Interim Results
Notice of Interim Results Announcement – Analyst Presentation
Hikma upgrades 2013 Group revenue guidance
AGM and Interim Management Statement
Hikma Pharmaceuticals strongly objects to the use of its products in capital punishment
Hikma signs licensing and marketing agreement for Dance Biopharm’s inhaled insulin in MENA
Hikma provides update on its global Injectables business
Hikma Pharmaceuticals Preliminary Results
Notice of Prelim Results Announcement – Analyst Presentation
Hikma agrees to acquire the Egyptian Company for Pharmaceuticals & Chemical Industries, strengthening its position in the large and fast growing Egyptian market
Hikma to present at the 31st Annual J.P. Morgan Healthcare Conference
Hikma Pharmaceuticals for Investing in Healthcare at the World Economic Forum Dead Sea 2013
Hikma Pharmaceuticals enhances employees performance through Training Sessions and Workshops
Hikma Pharmaceuticals launches its “Global Volunteering Campaign” with INJAZ’s “Young Volunteer Day”
Hikma Pharmaceuticals Invites Top Organizations to 'Towards a Smoke-Free Environment' Session
Hikma licenses VIBATIV® from Theravance
Hikma signs agreement with Sinclair IS Pharma to license Flammacerium for the MENA region
Hikma signs a licensing and distribution agreement with EffRx for its innovative osteoporosis medication
Hikma receives approval for Phenylephrine HCl Injection, USP
Interim Management Statement
Hikma Pharmaceuticals Receives IFC Client Leadership Award
Hikma Injectables Analyst and Investor Day
Notice - Hikma Injectables Analyst and Investor Day US
Hikma Pharmaceuticals Interim Results
Notice of Interim Results Announcement 2012 - Analyst Presentation
AGM and Interim Management Statement
Hikma Pharmaceuticals Preliminary Results
Notice for Preliminary Results 2011
Hikma Holds its Annual Training Workshops for Human Resources and Corporate Responsibility Employees
Hikma Pharmaceuticals Stages ‘You Are Hikma’ Annual Employee Welfare Week
Hikma Participates in CSR Conference at American University of Beirut
Hikma Pharmaceuticals Supports National Strategy to Combat Chronic Diseases
Hikma Pharmaceuticals Celebrates its Global Volunteering Day
Hikma Pharmaceuticals Joins Efforts with King Abdullah II Center for Excellence and King Hussein Cancer Center to Create Smoke-Free Environments
Hikma launches argatroban injection
Hikma signs license and supply agreement with GP Pharm for its leading oncology compound
Hikma Pharmaceuticals partners with Ergomed for clinical trials of anti-cancer medication
Hikma receives approval of its NDA for Argatroban Injection, 100mg/mL vial
Hikma Pharmaceuticals Supports PACES Initiative
Hikma launches therapeutic heparin in the US market
Hikma in-licenses major proprietary injectable product Ferinject® for the MENA region
Hikma Holds Global Volunteering Day For The 4th Consecutive Year
Hikma Pharmaceuticals Signs Agreement to Develop an Industrial Pharmaceuticals Faculty
Samih Darwazah Center for Innovation Management and Entrepreneurship Launched at American University of Beirut
Pioneering study reveals 7 out of 10 heart attack patients have diabetes
Hikma Receives FDA Approval for Cancer Drug Irinotecan
Hikma introduces Respirox to the Tunisian market
New Anti-Infective Products launched
Hikma CEO Speaks at Harvard School of Public Health’s MENA Conference
Hikma Pharmaceuticals Holds Diabetes Awareness Campaign
Hikma Pharmaceuticals Holds Anti-Obesity Campaign
Hikma Pharmaceuticals Holds Breast Cancer Awareness Campaign
Hikma Pharmaceuticals And The Children’s Museum Jordan Enter A New Partnership
‘You Are Hikma‘ Campaign
Hikma raises Awareness for Breast Cancer from Saudi Arabia to the United States
Hikma engages with its communities on World Diabetes Day 2009
Hikma and Winterlight Labs collaborate to develop biomarkers for Schizophrenia patients in MENA
Hikma announces global partnership with Direct Relief
Hikma to present at 42nd Annual J.P. Morgan Healthcare Conference
Activ Surgical, a Hikma Ventures portfolio company, completes the first international procedure using ActivSight™ Intelligent Light at Abdali Hospital in Jordan
Hikma appoints Julie Hill, as Senior Vice President, Corporate Quality Compliance/Health and Safety
Notice of preliminary results
Hikma Announces Agreement in Principle for Nationwide US Opioid Settlement Framework
Hikma announces US launch of COMBOGESIC® IV
Hikma delivers strong H1 performance and raises Generics guidance
Hikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseases
Hikma and SK Biopharmaceuticals enter a strategic partnership for the Middle East and North Africa
Hikma remains a constituent of the FTSE4Good Index
Hikma launches Vancomycin Hydrochloride for Injection, USP, in the US
Hikma launches generic version of Vyvanse® following FDA approval
Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US
Hikma and Cosmo partner on exclusive licensing agreement for Winlevi® (Clascoterone) for the Middle East and North Africa
Hikma launches Levocarnitine Injection, USP, in the US
Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa
Hikma launches Phenylephrine HCl Injection, USP, in ready-to-use vials in the US
Hikma continues strong momentum across the Group and upgrades guidance for 2023
Company Secretary Change
Hikma launches Alvimopan Capsules in the US
Hikma launches Fentanyl Citrate Injection, USP, in a prefilled syringe in the US
Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility
Hikma delivers strong 2023 performance and a positive outlook for 2024
Hikma’s Executive Vice Chairman and President of MENA Joins Rakuten Medical’s Board of Directors
Hikma appoints Dr. Hafrun Fridriksdottir as President of Generics business
Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated
Bringing Better Health Within Reach: Hikma’s journey to become the Partner of choice in MENA
Hikma launches Midazolam Injection, USP, in a prefilled syringe in the US
Hikma enters the Spanish generic injectables market, strengthening its European presence
Hikma opens new UK office to support NHS supply, strengthening European presence
Hikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House meeting
Hikma acquires Xellia’s differentiated portfolio and enhances Injectables pipeline, manufacturing capabilities and R&D
Hikma – A legacy of quality for a better future
Hikma launches Sodium Acetate Injection, USP, in the US
Notice of results
Hikma Pharmaceuticals Receives Permanent J-Code for COMBOGESIC® IV (acetaminophen and ibuprofen) injection from Centers for Medicare & Medicaid Services (CMS)
Hikma Pharmaceuticals USA Inc. Extends Voluntary Nationwide Recall of One Lot of Acetaminophen Injection, 1000mg/100mL, (10mg/mL) Bags Due to an Individual Unit of Acetaminophen Overwrap Found to Have Contained a Labelled Bag of Dexmedetomidine HCL Injection (400mcg/100mL)
Hikma Pharmaceuticals: how our three businesses work together to improve health
Hikma delivers strong H1 performance and upgrades Group guidance
KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months
Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day
Bringing Better Health Within Reach: Improving access to medicine as the partner of choice in MENA
Hikma launches Clindamycin in 5% Dextrose Injection in the US
Hikma completes Xellia acquisition
Hikma launches Foscarnet Sodium Injection, in the US
Hikma celebrates 40 years of Hatch-Waxman drug savings
Empowering lives - Hikma’s regional blood donation drives across MENA
Hikma's leadership receives prestigious recognitions in 2024
Hikma continues strong strategic execution and reiterates guidance
Celebrating Global Biosimilars Week: Hikma champions access to essential medicines for patients in the MENA region
Sell-side analysts and investors visit Hikma Casablanca site
Hikma launches Furosemide Injection, USP, in the US
Hikma and Richter announce FDA submission acceptance for Denosumab biosimilar products
Hikma acquires the rights to a portfolio of Takeda brands for the MENA region
Hikma launches Indomethacin Suppositories in the US
Hikma receives FDA approval and launches the generic version of Victoza®, Liraglutide, in the US
Hikma launches ePHEDrine Sulfate Injection, USP in the US
Hikma to present at 43rd Annual J.P. Morgan Healthcare Conference
Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg
Hikma launches Meropenem for Injection, USP in the US
Hikma and M42 sign strategic MOU to advance healthcare innovation in the UAE
Notice of results
Strong 2024 performance and a positive outlook for 2025
Hikma receives FDA approval and launches Mercaptopurine Oral Suspension in the US
Hikma to host meet the management and site visit in Columbus, Ohio
Shaping a healthier world by developing our pipeline in growing therapeutic areas
Shaping a healthier world by focusing on our quality manufacturing
Shaping a healthier world by expanding our patient reach across our markets
Shaping a healthier world by investing for the future
Shaping a healthier world by leveraging our role as a leading healthcare provider in MENA
Providing access to clean water for families in Egypt
Supporting food banks for those in need
Supporting education with UNHCR
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Hikma launches Cisatracurium Besylate Injection, USP in the US
Hikma: where our purpose inspires our people.
Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA
Inspiring women of Hikma. Meet Nesrine Nouhi, General Manager of Hikma France
Hikma acquires Novugen’s FDA-approved ANDA for trametinib
Hikma reiterates full year guidance following good start to the year
Hikma announces settlement agreement for Xyrem® (sodium oxybate) U.S. class action lawsuits
S&P upgrades Hikma Pharmaceuticals PLC and its Senior Notes to ‘BBB’ on continued good business momentum; outlook stable
Hikma announces strong medium-term Group guidance ahead of its US site visit
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
Inspiring women of Hikma - Meet Stephanie Haas, Senior Director, Head of Hikma Rx Procurement
Hikma launches Triamcinolone Acetonide Injectable Suspension, USP, in the US
Fitch upgrades Hikma Pharmaceuticals PLC’s long-term issuer default rating to ‘BBB’, outlook stable
Meet Ashanti Finley, Specialist in the People Function team at Berkeley Heights, US. Hear what she has to say about life at Hikma. #OwnYourCareer
Meet Rawand Batarseh, Sr. Brand Manager, Injectables, MENA. Hear what she has to say about life at Hikma. #OwnYourCareer
Meet Nawras A. BnyYassien, Health, Safety, and Environment, Manager for Hikma Chemical and Hikma Jordan. Hear what he has to say about life at Hikma. #OwnYourCareer
Meet Mariam Mukarker, Manager, Quality, MENA. Hear what she has to say about life at Hikma. #OwnYourCareer
Meet Malek Saleem, Finance Manager, Injectables, MENA. Hear what he has to say about life at Hikma. #OwnYourCareer
Meet Maya Beano, Pipeline Selection Manager, Injectables, MENA. Hear what she has to say about life at Hikma. #OwnYourCareer
Manufacturing Inventory Control Supervisor in the US. Hear what she has to say about life at Hikma. #OwnYourCareer
Meet Nika Beck, Manufacturing Specialist at Hikma 503B in the US. Hear what she has to say about life at Hikma. #OwnYourCareer
Meet Majda Lhoufati, Plant Manager in Morocco. Hear what she has to say about life at Hikma. #OwnYourCareer
Hikma launches Methylene Blue Injection, USP in the US
Meet Nika Beck and learn more about how she champions quality
Meet Osama Alrifai and learn more about how he champions quality
Meet Lisa Hurley and learn more about how she champions quality
Keeping patients safe is at the heart of everything we do
Shaping a healthier world: Our breast cancer awareness campaigns
Fostering connection and compassion: Hikma’s Community Dinner in Portugal
Hikma joins forces with the Jordan Hashemite Charity Organisation to establish and operate the Charity Clothes Bank
Inspiring creativity, empowering youth: Transforming the Art Studio at Camp Oty’Okwa
Hikma’s Cherry Hill site wins Governor’s Environmental Excellence Award in the US
Expanding our onsite renewable energy Generation
Inspiring women of Hikma - Meet Judy Bock, Associate Director, Quality Assurance
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Hikma publishes its 2024 Sustainability Report reinforcing commitment to global access to medicines
Hikma R&D Analytical Research Innovation. Meet Samuel Cook
Meet Farah Alasali, Senior Officer in our Social Responsibility team based in Jordan. Hear what she has to say about life at Hikma. #OwnYourCareer
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
Supporting communities globally: Highlights from our 2025 Global Volunteer Campaign
Notice of results
Hikma launches Morphine Sulfate Injection, USP, in a prefilled syringe in the US
Hikma remains a constituent of the FTSE4Good Index
Hikma R&D Innovating Analytical Research. Meet Saras Konar
Hikma R&D Innovating analytical research. Meet Raghad Saleh
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half
Hikma R&D Innovating Clinical Research. Meet Rand Alsaber
Strategic insights into Hikma Injectables CMO. Q&A with Tiago Duarte
Inspiring women of Hikma. Meet Dr Nina Diaz, General Manager of Hikma Thymoorgan, Germany
Acting responsibly for purpose-driven impact: How Hikma champions inclusive education
Hikma R&D Formulation Development Innovation. Meet Mihir Modh
Hikma R&D Analytical Research Innovation. Meet Seham Samawi
Hikma R&D Formulation Development Innovation. Meet Timothy Owen
Meet Jaclyn Bachman, Associate Director Validations & Metrology, Cherry Hill, US. Injectables division
Hikma and Richter receive FDA approval for denosumab biosimilars EnobyTM (denosumab- qbde) and XtrenboTM (denosumab- qbde) referencing Prolia® and Xgeva® respectively
Hikma R&D Innovating formulation development. Meet Helena Sremec
Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA
Driving pharmaceutical excellence and growth in Pavia: A Q&A with Roberto Gagliano, General Manager, Hikma Italia
Inspiring women of Hikma. Meet Christine Schneider, General Manager, Hikma Germany
Hikma R&D. Innovating formulation development. Meet Anas Younues
Hikma R&D. Innovating analytical development. Meet Edvin Brusač
Hikma confirms 2025 guidance and updates medium-term growth outlook
Hikma R&D. Innovating Formulation Development. Meet Razan Alsawwaf
Hikma Pharmaceuticals announces the launch of STARJEMZA™ (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
Strategic priorities in Hikma Pharmaceuticals R&D: Q&A with Hafrun Fridriksdottir, President, Rx and R&D
Hikma signs an exclusive agreement with DGI Group to bring Claritag® to the MENA region
Inspiring women of Hikma - Meet Susana Pereira Sr. Director Quality Systems & Validation – EU & MENA Injectables
Hikma celebrates 20 years on the London Stock Exchange
European Injectables growth: a Q&A with Nassim Rahmani, Associate VP, Commercial Europe & Canada
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
Hikma announces CEO change and Board appointment
Inspiring women of Hikma - Meet Cristina Cagnazzi, Finance Director, Hikma Italy
Supporting Breast Cancer Awareness Month at Hikma
Exploring partnership opportunities with Hikma Pharmaceuticals
Hikma achieves B scores in Climate Change and Water Security in 2025 CDP assessment
Hikma announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respectively
Notice of results
Hikma R&D. Innovation in clinical research. Meet Hiba Kamal
Inspired at Hikma. Meet Ana Santos Perez
Hikma launches authorised generic of Nucynta® (tapentadol) in the US
Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
Hikma launches authorised generic of Nucynta® ER (tapentadol) extended-release in the US
Hikma R&D. Innovation in formulation development. Meet Hamza Qassim
Investing in R&D to drive high-value pipeline delivery
Investing in manufacturing excellence at Hikma
Investing in MENA to expand access and drive growth
Investing in strategic partnerships driving growth in the US and MENA
Investing in the development of our people for long‑term growth
Putting patients first through quality: a Q&A with Tyson Ardo, Associate Vice President, Quality
Hikma reiterates full year 2026 guidance following encouraging start to the year
Inside Injectables: A Q&A with Natheer Masarweh, SVP of Injectables Operations | Manufacturing Today
Building resilience in water stressed regions
Hikma France obtains A++ Green Index Rating for the third year running
Hikma Jordan office achieves LEED Gold Certification for sustainable operations
Hikma announces settlement agreement for VYNDAMAX® (tafamidis)
Hikma Pharmaceuticals and Marius Pharmaceuticals announce licensing agreement for KYZATREX® (testosterone undecanoate) CIII capsules in Canada
Contact
US locations
Europe locations
MENA locations
Canada locations
Document hub
Useful Links
Report a possible adverse event
Terms of use
Disclaimer
Privacy policy
Community guidelines
Modern Slavery Act statement
Subscribe
Cookie policy
Locations
Algérie
Canada
Egypt
France
Germany
Iraq
Italy
Jordan
KSA
Morocco
Netherlands
Portugal
Spain
Tunisia
UAE
UK
US
Individual Rights Request Form